- United States
- Medical Equipment
Integra LifeSciences Holdings Insiders Sold US$917k Of Shares Suggesting Hesitancy \
Integra LifeSciences Holdings Corporation (NASDAQ:IART) shareholders may have reason to be concerned, as several insiders sold their shares over the past year. Knowing whether insiders are buying is usually more helpful when evaluating insider transactions, as insider selling can have various explanations. However, if numerous insiders are selling, shareholders should investigate more.
While we would never suggest that investors should base their decisions solely on what the directors of a company have been doing, logic dictates you should pay some attention to whether insiders are buying or selling shares.
View our latest analysis for Integra LifeSciences Holdings
Integra LifeSciences Holdings Insider Transactions Over The Last Year
Over the last year, we can see that the biggest insider sale was by the Independent Director, Raymond Murphy, for US$446k worth of shares, at about US$55.78 per share. While we don’t usually like to see insider selling, it’s more concerning if the sales take place at a lower price. The good news is that this large sale was at well above current price of US$39.64. So it is hard to draw any strong conclusion from it.
Happily, we note that in the last year insiders paid US$400k for 10.43k shares. But they sold 16.39k shares for US$917k. Over the last year we saw more insider selling of Integra LifeSciences Holdings shares, than buying. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!
I will like Integra LifeSciences Holdings better if I see some big insider buys. While we wait, check out this free list of growing companies with considerable, recent, insider buying.
Integra LifeSciences Holdings Insiders Bought Stock Recently
There has been significantly more insider buying, than selling, at Integra LifeSciences Holdings, over the last three months. In fact, two insiders bought US$400k worth of shares. On the other hand, Executive VP & President of Codman Specialty Surgical Michael McBreen netted US$100k by selling. The buying outweighs the selling, which suggests that insiders may believe the company will do well in the future.
Does Integra LifeSciences Holdings Boast High Insider Ownership?
Many investors like to check how much of a company is owned by insiders. I reckon it’s a good sign if insiders own a significant number of shares in the company. It appears that Integra LifeSciences Holdings insiders own 3.1% of the company, worth about US$99m. This level of insider ownership is good but just short of being particularly stand-out. It certainly does suggest a reasonable degree of alignment.
So What Does This Data Suggest About Integra LifeSciences Holdings Insiders?
The recent insider purchases are heartening. But we can’t say the same for the transactions over the last 12 months. We don’t take much heart from transactions by Integra LifeSciences Holdings insiders over the last year. But they own a reasonable amount of the company, and there was some buying recently. So they seem pretty well aligned, overall. In addition to knowing about insider transactions going on, it’s beneficial to identify the risks facing Integra LifeSciences Holdings. You’d be interested to know, that we found 1 warning sign for Integra LifeSciences Holdings and we suggest you have a look.
But note: Integra LifeSciences Holdings may not be the best stock to buy. So take a peek at this free list of interesting companies with high ROE and low debt.
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.
Valuation is complex, but we’re helping make it simple.
Find out whether Integra LifeSciences Holdings is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.
View the Free Analysis
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Integra LifeSciences Holdings
Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care and otolaryngology.
Undervalued with moderate growth potential.